These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26042899)

  • 1. The reproductive outcome of women with hypogonadotropic hypogonadism undergoing in vitro fertilization.
    Yilmaz S; Ozgu-Erdinc AS; Yumusak O; Kahyaoglu S; Seckin B; Yilmaz N
    Syst Biol Reprod Med; 2015; 61(4):228-32. PubMed ID: 26042899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
    Jiang S; Kuang Y
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Women with hypogonadotropic hypogonadism: cycle characteristics and results of assisted reproductive techniques.
    Kumbak B; Kahraman S
    Acta Obstet Gynecol Scand; 2006; 85(12):1453-7. PubMed ID: 17260221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of ovulation induction and intrauterine insemination in infertile patients with hypogonadotropic hypogonadism.
    Huseyin K; Berk B; Tolga K; Eser O; Ali G; Murat A
    J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):833-838. PubMed ID: 30930300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of hypogonadotropic hypogonadism on ovarian reserve and response.
    Cecchino GN; Canillas GM; Cruz M; García-Velasco JA
    J Assist Reprod Genet; 2019 Nov; 36(11):2379-2384. PubMed ID: 31625035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Reproductive Outcome of Women with Hypogonadotropic Hypogonadism in IVF.
    Zhang CM; Zhang H; Yang R; Chen LX; Liu P; Li R; Qiao J; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():850126. PubMed ID: 35733765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The reproductive performance of women with hypogonadotropic hypogonadism in an in vitro fertilization and embryo transfer program.
    Ulug U; Ben-Shlomo I; Tosun S; Erden HF; Akman MA; Bahceci M
    J Assist Reprod Genet; 2005 Apr; 22(4):167-71. PubMed ID: 16021861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
    Escudero EL; Boerrigter PJ; Bennink HJ; Epifanio R; Horcajadas JA; Olivennes F; Pellicer A; Simón C
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2081-8. PubMed ID: 15483085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
    Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
    J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety.
    Ashrafi M; Kiani K; Ghasemi A; Rastegar F; Nabavi M
    Arch Gynecol Obstet; 2011 Dec; 284(6):1431-8. PubMed ID: 21210134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
    European Recombinant LH Study Group
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
    Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
    Kim CH; Ahn JW; You RM; Kim SH; Chae HD; Kang BM
    J Reprod Med; 2014; 59(1-2):63-8. PubMed ID: 24597289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LH supplementation in mild stimulations cycles without pituitary suppression: a retrospective analysis.
    Paragona M; Rossini M; Dattilo M; Stamm J
    Gynecol Endocrinol; 2013 Feb; 29(2):101-4. PubMed ID: 23256611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.